BLACKPOOL TEACHING HOSPITALS NHS FOUNDATION TRUST

Physiomics' PREDICT-ONC Trial Receives Approval to Optimize Chemotherapy Dosing

5 months ago

• Physiomics' PREDICT-ONC project, designed to refine personalized chemotherapy dosing, has received regulatory and ethical approval to proceed with its observational trial. • The trial will evaluate software's ability to predict GCSF dosing, a drug used to counteract neutropenia, a common side effect of chemotherapy, in breast cancer patients. • The PREDICT-ONC project aims to optimize chemotherapy dosing for individual patients, potentially improving patient outcomes and reducing the toxic effects of treatment. • Recruitment for the trial, conducted in partnership with Beyond Blood Diagnostics and Blackpool Teaching Hospitals, is expected to begin imminently, with completion projected for late 2025.